Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPI 287 in Advanced Pancreatic Cancer
NCT00553813Phase 2Terminated
- Sponsor
- Cortice Biosciences Inc.
- Start
- Oct 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of abeotaxane in pancreatic ductal adenocarcinoma (PDAC) and undifferentiated carcinoma of the pancreas (PUC), sponsored by Cortice Biosciences Inc. Primary endpoint: 6-Month Survival Rate. Started Oct 2007; status: terminated.
02
Drugs
abeotaxane
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)undifferentiated carcinoma of the pancreas (PUC)
Beyond the preview
Go deeper on NCT00553813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553813.